Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1250 of 1380 results for patients and public

  1. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  2. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    In development [GID-TA11215] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. ONS-5010 for treating wet age-related macular degeneration ID6320

    In development [GID-TA11193] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  7. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development [GID-TA11199] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development [GID-TA11351] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development [GID-TA11298] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

    In development [GID-TA10733] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  13. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  14. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  15. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  16. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: 30 October 2024

    Highly specialised technologies guidance
    In development

  17. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Topical Antimicrobial dressings for wound care: Late stage assessment

    In development [GID-HTE10041] Expected publication date: TBC

    Health technology evaluations
    In development

  19. Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]

    In development [GID-TA11418] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  20. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Awaiting development [GID-TA11396] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

    In development [GID-TA10962] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  25. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  26. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued

  27. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury

    Awaiting development [GID-IPG10367] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  28. Phrenic nerve pacing for congenital central hypoventilation syndrome

    Awaiting development [GID-IPG10317] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  29. Caval valve implantation for tricuspid regurgitation

    Awaiting development [GID-IPG10344] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  30. Linzagolix for treating pain caused by endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Targeted Muscle Reinnervation for refractory pain after limb amputation

    Awaiting development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    Awaiting development

  32. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  33. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]

    Awaiting development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  37. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Zuranolone for treating severe postnatal depression ID6431

    Awaiting development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Artificial intelligence software to help detect fractures in the emergency department (provisional title)

    In development [GID-HTE10044] Expected publication date: 17 December 2024

    Health technology evaluations
    In development

  43. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  44. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  46. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  50. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development